Biological Injectables for OA; What, When and Why? Sum Up

Description

In this segment, Fares Haddad discusses crucial topics surrounding orthopedic solutions and the complexities involved in developing effective treatments. He emphasizes the need for clarity and guidance from the Board of Advisors (BOA) on treatment protocols, especially given the varied targets and possible solutions that may arise from recent research. Haddad acknowledges researchers such as Connie, Chu, Daniel, and Sarris for their promising contributions to the field, illustrating a collective pursuit of what he describes as the 'Holy Grail for orthopedics.' He also advises caution against being influenced by industry marketing that lacks robust evidence, insisting on the necessity for safe, well-supported interventions. Furthermore, he highlights the importance of collaboration with regulatory bodies like the MHRA to ensure that innovative treatments are responsibly integrated into patient care while preventing ineffective options from being proposed.

DOI: 10.1302/3114-221769

Specialties